ADMA Biologics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Its last 3 Sell calls were actually followed by a +11% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +7.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 8.1% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 17.1x | Better than 51% |
| Forward P/E | 16.5x | Better than 50% |
| Price / Sales | 5.8x | Better than 19% |
| P/E vs own 5-yr range | 69th pctl | Better than 39% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 57.4% | Better than 71% |
| Operating margin | 37.5% | Better than 94% |
| Net margin | 28.8% | Better than 89% |
| Return on equity | 35.6% | Better than 90% |
| Return on invested capital | 30.6% | Better than 96% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 33.8% | Better than 99% |
| 6-month return | 59.8% | Better than 96% |
| 12-month return (ex latest month) | -37.8% | Better than 6% |
| Distance below 52-week high | 35.6% | Better than 34% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.7x | Better than 90% |
| Debt to assets | 12.8% | Better than 66% |
| Interest coverage | 26.7x | Better than 85% |
| Free cash flow / net income | 18.7% | Better than 5% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 66.7% | Better than 41% |
| Upside to average target | 26.6% | Better than 43% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 13.34
- Open
- 13.26
- Day range
- 13.10 - 13.47
- Avg price
- 13.21
- Volume
- 2.45M
- Turnover
- 32.35M
- Turnover ratei
- 1.19%
- Volume ratioi
- 0.72
- Amplitudei
- 2.77%
- 52-week rangei
- 7.21 - 20.46
Valuation
- P/Ei
- 21.95
- P/E (TTM)i
- 17.10
- P/Bi
- 6.66
- EPSi
- 0.60
- Book value / shi
- 1.98
- Net profit
- 133.11M
- Net assets
- 438.61M
Share structure
- Market cap
- 2.92B
- Float capi
- 2.70B
- Shares out
- 221.85M
- Float sharesi
- 205.22M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
35.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-16.80M net over the window
Short interest
- Shares short
- 18.04M
- % of floati
- 8.05%
- Days to coveri
- 7.11
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of ADMA Biologics (ADMA)?
ADMA Biologics last traded at 13.17. This page shows a periodic quote snapshot. Check the displayed quote time.
What is ADMA Biologics's market cap?
About 2.92B.
What is the P/E ratio of ADMA Biologics?
The trailing twelve-month P/E is 17.10. The Valuation tab shows it against the stock's own five-year range.
Does ADMA Biologics pay a dividend?
ADMA Biologics does not currently pay a regular dividend.
Is ADMA Biologics a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 16.67, which implies 26.6% upside from the current price. This is not investment advice.
What is ADMA Biologics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ADMA Biologics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ADMA Biologics discussion 0 comments